NCT03217604View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

Treatment with placebo

DRUG

PF-06852231

Treatment with PF-06852231

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY